Cite
HARVARD Citation
Zinzani, P. et al. (2020). Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leukemia & lymphoma. 61 (4), pp. 950-954. [Online].